Literature DB >> 18522245

Embryonic substantia nigra grafts show directional outgrowth to cografted striatal grafts and potential for pathway reconstruction in nonhuman primate.

J R Sladek1, K B Bjugstad, T J Collier, E A Bundock, B C Blanchard, J D Elsworth, R H Roth, D E Redmond.   

Abstract

Transplantation of embryonic dopamine (DA) neurons has been tested as a therapy for Parkinson's disease. Most studies placed DA neurons into the striatum instead of the substantia nigra (SN). Reconstruction of this DA pathway could serve to establish a more favorable environment for control of DA release by grafted neurons. To test this we used cografts of striatum to stimulate growth of DA axons from embryonic SN that was implanted adjacent to the host SN in African green monkeys. Embryonic striatum was implanted at one of three progressive distances rostral to the SN. Immunohistochemical analysis revealed DA neuron survival and neuritic outgrowth from the SN grafts at 12-36 weeks after grafting. Each animal showed survival of substantial numbers of DA neurons. Most fibers that exited SN grafts coursed rostrally. Striatal grafts showed evidence of target-directed outgrowth and contained dense patterns of DA axons that could be traced from their origin in the SN grafts. A polarity existed for DA neurites that exited the grafts; that is, those seen caudal to the grafts did not appear to be organized into a directional outflow while those on the rostral side were arranged in linear profiles coursing toward the striatal grafts. Some TH fibers that reached the striatal grafts appeared to arise from the residual DA neurons of the SN. These findings suggest that grafted DA neurons can extend neurites toward a desired target over several millimeters through the brain stem and caudal diencephalon of the monkey brain, which favors the prospect of circuit reconstruction from grafted neurons placed into appropriate locations in their neural circuitry. Further study will assess the degree to which this approach can be used to restore motor balance in the nonhuman primate following neural transplantation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18522245

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  11 in total

1.  Cell Therapy From Bench to Bedside Translation in CNS Neurorestoratology Era.

Authors:  Hongyun Huang; Lin Chen; Paul Sanberg
Journal:  Cell Med       Date:  2010-01-01

Review 2.  Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease.

Authors:  James P Harris; Justin C Burrell; Laura A Struzyna; H Isaac Chen; Mijail D Serruya; John A Wolf; John E Duda; D Kacy Cullen
Journal:  NPJ Parkinsons Dis       Date:  2020-01-08

Review 3.  Cellular repair in the parkinsonian nonhuman primate brain.

Authors:  Donald Eugene Redmond; Stephanie Weiss; John D Elsworth; Robert H Roth; Dustin R Wakeman; Kimberly B Bjugstad; Timothy J Collier; Barbara C Blanchard; Yang D Teng; Evan Y Synder; John R Sladek
Journal:  Rejuvenation Res       Date:  2010 Apr-Jun       Impact factor: 4.663

4.  Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non-human primate after overexpression of GDNF.

Authors:  D E Redmond; J D Elsworth; R H Roth; C Leranth; T J Collier; B Blanchard; K B Bjugstad; R J Samulski; P Aebischer; J R Sladek
Journal:  J Comp Neurol       Date:  2009-07-01       Impact factor: 3.215

5.  Comparison of fetal mesencephalic grafts, AAV-delivered GDNF, and both combined in an MPTP-induced nonhuman primate Parkinson's model.

Authors:  D Eugene Redmond; Caleb R S McEntire; Joseph P Kingsbery; Csaba Leranth; John D Elsworth; Kimberly B Bjugstad; Robert H Roth; Richard J Samulski; John R Sladek
Journal:  Mol Ther       Date:  2013-08-05       Impact factor: 11.454

Review 6.  Cell-based therapies for Parkinson's disease: past, present, and future.

Authors:  Kathleen M Fitzpatrick; James Raschke; Marina E Emborg
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

7.  Dopaminergic neurons from midbrain-specified human embryonic stem cell-derived neural stem cells engrafted in a monkey model of Parkinson's disease.

Authors:  Marcel M Daadi; Brad A Grueter; Robert C Malenka; D Eugene Redmond; Gary K Steinberg
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

Review 8.  The role of nonhuman primate models in the development of cell-based therapies for Parkinson's disease.

Authors:  Scott C Vermilyea; Marina E Emborg
Journal:  J Neural Transm (Vienna)       Date:  2017-03-22       Impact factor: 3.575

Review 9.  Restoring lost nigrostriatal fibers in Parkinson's disease based on clinically-inspired design criteria.

Authors:  Wisberty J Gordián-Vélez; Dimple Chouhan; Rodrigo A España; H Isaac Chen; Jason A Burdick; John E Duda; D Kacy Cullen
Journal:  Brain Res Bull       Date:  2021-07-28       Impact factor: 3.715

10.  The rat striatum responds to nigro-striatal degeneration via the increased expression of proteins associated with growth and regeneration of neuronal circuitry.

Authors:  Heidi R Fuller; Maica Llavero Hurtado; Thomas M Wishart; Monte A Gates
Journal:  Proteome Sci       Date:  2014-04-28       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.